Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo may slash radiation harm in rare lymphoma

NCT ID NCT07554482

Not yet recruiting Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug selinexor to a lower dose of radiation can treat early-stage NK/T-cell lymphoma just as well as standard high-dose radiation, but with fewer side effects. About 34 people who have not had prior treatment will receive chemotherapy first, then selinexor plus 40 Gy radiation. The goal is to see if this approach keeps the cancer under control while reducing mouth sores and dry mouth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma Lymphoma, Extranodal NK-T-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTRANODAL NK/T-CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, 100730, China